Debate on Approval of Sarepta's Gene Therapy for Duchenne Muscular Dystrophy

This chapter discusses the ongoing debate within the biotech community regarding the approval of a certain drug. One side argues that the trial doesn't work and highlights the flaws in the data, while the other side consists of desperate families who believe the drug could help their children. The discussion also touches upon the FDA's handling of such situations and the history of debates and overrulings involving this particular company. It emphasizes the contentious nature of the conversation that has been ongoing for years and the importance of regulating medicines effectively.